Cart
sales@molnova.com
Valbenazine
CAS No. 1025504-45-3
Valbenazine ( NBI-98854 )
Catalog No. M10117 CAS No. 1025504-45-3
A novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 60 | In Stock |
|
| 5MG | 122 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 402 | In Stock |
|
| 50MG | 582 | In Stock |
|
| 100MG | 831 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameValbenazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.
-
DescriptionA novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia.Other Indication Phase 3 Clinical
-
SynonymsNBI-98854
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research AreaOther Indications
-
IndicationOther Disease
Chemical Information
-
CAS Number1025504-45-3
-
Formula Weight418.57
-
Molecular FormulaC24H38N2O4
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1OC(=O)C(C(C)C)N)OC)OC
-
Chemical NameL-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-yl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. O'Brien CF, et al. Mov Disord. 2015 Oct;30(12):1681-7.
molnova catalog
related products
-
Fraxetin
Extracted from Fraxinus brngeana DC.
-
Morniflumate
Morniflumate is a nonsteroidal anti-inflammatory drug. It is used to treat inflammation.
-
Protein Kinase C Pep...
Protein Kinase C Peptide Substrate targets specific cell spacers ina manner that is dependent on second messengers and specific adaptor proteins in response to extracellular signals that activate g protein-coupled receptors, tyrosine Kinase receptors, or tyrosine kinase-coupled receptors.
